Advertisement
Articles
Subscribe to Drug Discovery & Development Articles

The Lead

Pipeline Advancements, Asset Acquisitions Fueled Mid-Cap Biotech R&D Spend in 2014

April 23, 2015 | by Adam Dion, GlobalData's Senior Industry Analyst | Comments

The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014. Read more...

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Bristol-Myers Gets Positive EMA Opinion for Immunotherapy Drug, Opdivo

April 24, 2015 12:36 pm | by Stephanie Guzowski, Editor | Comments

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Bristol-Myers Squibb’s Opdivo today for the treatment of melanoma. Read more..

TOPICS:

AACR 2015: Pembrolizumab Comes Out on Top for Melanoma, Lung Cancer

April 22, 2015 10:33 am | by Stephanie Guzowski, Editor | Comments

At the AACR Annual Meeting 2015, immunotherapies, called PD-1 inhibitors, were front and center stage, due to clinical trial results that led to U.S. Food and Drug Administration (FDA) approvals for treating melanoma and non-small cell lung cancer (NSCLC). Read more..

TOPICS:

Immunotherapy is Not a Curiosity Anymore

April 20, 2015 8:29 am | by Ryan Bushey, Associate Editor | Comments

One of the main sessions at this year’s Experimental Biology Conference in Boston was the Tang Prize Award lecture. Read more...

TOPICS:
Advertisement

Impact of Label-Free Cell-Based Assays and the Holistic Calorimetry Approach

April 17, 2015 10:23 am | by Magnus Jansson, Ph.D., CSO, SymCel Sverige AB | Comments

New, innovative technology solves challenges in antibiotic resistance and the drug development cycle. Read more...

TOPICS:

How PBPK Models Advance the Understanding of Therapeutic Antibodies

April 16, 2015 10:40 am | by Suzanne K. Minton, Ph.D., Scientific Content Specialist, Certara | Comments

Monoclonal antibodies (mAbs) are large Y-shaped proteins that are produced by immune cells to defend the body against pathogens. A hallmark of antibodies is their ability to specifically bind to epitopes, or the parts of the antigen that the immune system recognizes, on their molecular targets, which has been harnessed by drug companies to develop treatments for certain cancers and autoimmune diseases. Read more...

TOPICS:

Melanoma Treatment Market Value to More than Quadruple to $5.64 Billion by 2023

April 16, 2015 8:26 am | by Fenix Leung, DPhil, GlobalData’s Oncology and Hematology Analyst | Comments

The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated $5.64 billion by 2023. Read more...

TOPICS:

Harvard's Hope for the Future of Healthcare

April 14, 2015 8:49 am | by Ryan Bushey, Associate Editor | Comments

Shortcomings in the fast-evolving digital health care arena are becoming obvious. Read more...

TOPICS:

Coffee Protects DNA From Breaking, Say Two Recent Studies

April 13, 2015 3:47 pm | by Drug Discovery & Development Staff | Comments

Coffee drinking is often associated with lower rates of degenerative diseases, from Parkinson’s to cancers. Two recent studies support one theory why: coffee protects DNA from breaking, and quite shortly after it is consumed.

TOPICS:
Advertisement

Sanofi Executive: No Need to Discount New Diabetes Drug

April 13, 2015 1:20 pm | by Ryan Bushey, Associate Editor | Comments

Investors and financial analysts are worried about this decision. Read more...

TOPICS:

The First Personalized Genomic Cancer Vaccines

April 9, 2015 12:07 pm | by Cynthia Fox, Science Writer | Comments

The first personalized cancer vaccine using genomics to define targets elicits robust immune responses, says a recent Science study. Read more...

TOPICS:

Analyst: Top Mid-Cap Biotech Companies Increased Revenues to $26.5 Billion in 2014

April 8, 2015 8:21 am | by Adam Dion, Healthcare Industry Analyst, GlobalData | Comments

The combined total revenues for the peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014. Read more...

TOPICS:

Tau is the Main Culprit in Alzheimer’s, say Two Studies

April 7, 2015 5:17 pm | by Cynthia Fox, Science Writer | Comments

Two recent studies have concluded that tau, not amyloid, is the main driver behind Alzheimer’s disease (AD). Read more...

TOPICS:

Specialty Drug Prescription Service ZappRx Raises $5.6M

April 7, 2015 2:29 pm | by Ryan Bushey, Associate Editor | Comments

This brings the total funding for the Boston-based startup to 8.8 million. Read more...

TOPICS:

New R&D Alliance Forms to Find First-Ever Biomarker for Pancreatic Cancer

April 7, 2015 11:49 am | by Ryan Bushey, Associate Editor | Comments

This program will utilize a precision medicine approach to potentially find a cure for this disease. Read more...

TOPICS:

New Developments in Characterizing Protein-Small Molecule Interactions for Drug Discovery

April 6, 2015 4:26 pm | by Bill Sawka, MicroCal Product Manager, Malvern Instruments & Natalia Markova, Principal Scientist – MicroCal, Malvern Instruments | Comments

Isothermal titration calorimetry (ITC) is a highly valuable technique that is used throughout drug discovery workflow to study the binding interactions of proteins and small molecules. It is an essential tool for both drug design and the study and regulation of protein interactions. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading